TRVI241220C4000
- 0.61
- +0.23+60.53%
Trevi Therapeutics Newsroom
Trevi Therapeutics, Inc.'s (NASDAQ:TRVI) High Institutional Ownership Speaks for Itself as Stock Continues to Impress, up 38% Over Last Week
A Quick Look at Today's Ratings for Trevi Therapeutics(TRVI.US), With a Forecast Between $6 to $9
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Trending Stocks Today | Palisade Bio Shoots up 66.42%
Sector Update: Health Care Stocks Softer Thursday Afternoon
Top Midday Gainers
Sector Update: Health Care
Trevi Therapeutics Price Target Raised to $7.50/Share From $6.00 by HC Wainwright & Co.
Trevi Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Trevi Therapeutics Phase IIb Update a Major De-risking Event, Says B. Riley
H.C. Wainwright Ups Trevi Therapeutics Target After 'Best-case' for CORAL
Gold Falls Sharply; Adobe Shares Dip After Weak Revenue Outlook
Trevi Stock Rockets on Haduvio Study Update
Nasdaq Down 50 Points; US Initial Jobless Claims Rise
Trevi Therapeutics Shares Hit 52-Week High After Positive Trial Analysis
Why Is Cough-Focused Trevi Therapeutics Stock Skyrocketing On Thursday?
Optimistic Buy Rating for Trevi Therapeutics Amid Promising Phase 2b Trial Results
Keros KROS Phase 2 Dosing Halt; Trevi Therapeutics TRVI SSRE Review
Trevi Therapeutics Reaches 75% of Enrollment Target for Phase 2B IPF Chronic Cough Study
Trevi Therapeutics Shares Are Trading Higher After the Company Announced Positive Outcomes for the Treatment of Patients From Its Chronic Cough Phase 2b CORAL Trial.